UNSPSC 51282110: Floxacillin or flucloxacillin

This classification denotes a penicillin antibiotic with the molecular formula C19H17ClFN3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43B2M34G2V, chemically known as 6-(3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid but generally known as floxacillin, which bears US NIH Compound Identifier 21319. European Medicines Agency schedules Floxacillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07673MIG.

UNSPSC 51282110 Floxacillin or flucloxacillin is a Commodity code that, based on recent state and local solicitations, does not reflect actual procurement activity under this code's nominal scope. The recent opportunities posted under this designation instead involve naloxone procurement, direct-to-manufacturer pharmacy programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products — none of which align with floxacillin or flucloxacillin antibiotic sourcing. The mismatch suggests a tagging or classification error in the source data rather than legitimate activity under the antibiotic pharmaceutical commodity itself. State and local health departments, emergency management agencies, and cooperative purchasing alliances (including Seminole County, Florida; the Texas Health and Human Services Commission; the City of Tampa; and the Minnesota Multistate Cooperative Purchasing Alliance) have posted these opportunities, but they do not represent demand for the specific pharmaceutical named in the code.

The available opportunities span naloxone and drug deactivation systems (Seminole County IFB, due July 26, 2023); therapeutic pharmacy direct-to-manufacturer initiatives (Texas HHS RFI, due April 3, 2026); emergency medical and first aid supplies for fire rescue (City of Tampa IFB, due March 13, 2026, estimated $700,000 with SLBE set-asides); and broad multi-source generic pharmaceuticals and OTC products through cooperative purchasing (MMCAP RFP, due March 26, 2026, across Minnesota and Oregon). Geographic activity includes Florida, Texas, and Minnesota. Because the code shows no recent opportunities aligned with floxacillin or flucloxacillin procurement, business development professionals should treat this code as inactive or misclassified for targeting purposes and focus on the broader pharmaceutical and OTC commodity codes under which actual state and local health-system and emergency-response drug procurement occurs.